

What Product Makes a Difference?

Programme for International Forum on
“ICPD @ 15: Progress and Prospects”
Kampala, Uganda
November 24-25, 2008

Duff Gillespie
Department of Population, Family and Reproductive Health
The Bill and Melinda Gates Institute for Population and Reproductive Health


dgillesp@jhsph.edu

© 2008, Johns Hopkins University. All rights reserved.

No product, no program


**Yes, but what product a program
provides is important**

The importance of some reasons for non-use has changed over time




Slide source: Guttmacher Institute, *New evidence to address unmet need for contraception*, July 2007 presentation

Clients who receive their method of choice are more likely to continue using the method




Source: Pariani, *Studies in Family Planning*, Nov/Dec 1991.

Rising proportion of injectables in method mix concomitant with increase in CPR



Progestin levels: Levonorgestrel-containing contraceptives




Sources: Blumenthal PD, and Edelman A, Hormonal Contraception. *Obstetrics & Gynecology* 2008;112:670-684

Estrogen content of combined hormonal contraceptives

Delivery System	First Approved	Current Estrogen Content	Use	Failure Rates (Typical Use)
Oral Contraceptives	1960	30-35 micrograms	Daily	7.5-8.5%
Transdermal Patch	Nov 2001	20 micrograms	Once weekly	1-2%
Vaginal Ring	Oct 2001	15 micrograms	Once monthly	1-2%**

Sources: World Health Organization/Department of Reproductive Health and Research (WHO), Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs/INFO Project (CCP). *Family Planning: A Global Handbook for Providers*. Baltimore, MD and Geneva: CCP and WHO, 2007.

Hormonal Contraception: Alternate Delivery Options




A. Intrauterine system. B. Single-rod implant. C. Vaginal ring. D. Hormonal patch. E. The DEPO SQ Uniject system (Becton Dickinson, Franklin Lakes, NJ), a disposable, prefilled injection system.

Sources: Blumenthal PD, and Edelman A. Hormonal Contraception. *Obstetrics & Gynecology* 2008;112:670-684 and Victoria Graham. The USAID/Malawi Experience

Timeline of Depo-Provera

Increasing Access to Depo-Provera through Community-based Distribution (CBD) and an Innovative Syringe



Picture source: Victoria Graham. The USAID/Malawi Experience

Thank You

